Top 5 Radiopharmaceutical Companies

Radiopharmaceuticals are medicinal formulations that contain radioactive isotopes used for the diagnosis and treatment of various diseases. These compounds selectively localize in specific organs, tissues, or cellular targets, allowing for visualization or targeted radiotherapy. Radiopharmaceuticals regulate physiological functions by interacting with biological pathways and providing diagnostic or therapeutic information at the molecular level.

It is important to note that these molecules consist of a radionuclide linked to a carrier, typically a ligand or biomolecule, through a stable chemical bond. When radionuclides are attached to targeting vectors such as peptides or antibodies, they form radioconjugates that can precisely deliver radiation to the intended site of action. The highly controlled radiopharmaceutical manufacturing process is crucial to maintain the stability and biological function of these modalities.

Radiopharmaceuticals and radiotheranostics have emerged as a vital part of the precision medicine landscape. Over 410 radiopharmaceuticals are currently under investigation across different stages of development for treating various disorders, particularly cancer therapeutics. Their growing adoption can be attributed to their ability to diagnose and treat a wide range of oncological, cardiovascular, and neurological disorders with minimal side effects. Supported by technological innovations, increasing demand for targeted radioligand therapies, and expanding production capacities, the radiopharmaceuticals market is anticipated to witness robust and sustained growth in the long term.

Roots Analysis has conducted an exhaustive study on the Radiopharmaceuticals Market featuring the current market landscape and future opportunity for the companies engaged in developing radiopharmaceuticals, over a span of next 10 years.

Top Five Promising Radiopharmaceutical Companies

1. Novartis
2. Telix Pharmaceuticals
3. Bayer
4. Lantheus
5. ITM Isotope Technologies

The figure below highlights the top five radiopharmaceutical companies:

Interested in exploring all 100+ radiopharmaceutical companies and their recent initiatives?

Discover Below the Details on Top 5 Radiopharmaceutical Companies

Let us dive deep into the details of the top 5 radiopharmaceutical companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. Novartis

Company Overview

Novartis is a healthcare company focused on discovery, development and manufacturing of generic pharmaceutical and eye care products. The company offers a wide range of drugs with the primary focus on various therapeutic areas such as oncological disorders, cardiovascular disorders, dermatological disorders, neurological disorders and various other disorders. Novartis has a strong radiopharmaceuticals portfolio featuring innovative cancer treatments like Pluvicto® and Lutathera®. These therapies use targeted radiation to attack tumors precisely, offering new hope to patients with hard-to-treat cancers. The company is also investing in expanding its production facilities to support growth in this cutting-edge area.

Radiopharmaceutical Pipeline

The section provides information on the comprehensive radiopharmaceutical pipeline of Novartis, outlining the number of drugs for each therapeutic indication across various stages.

Commercialized Drugs:
Therapeutic Radiopharmaceuticals: Neuroendocrine Tumor (1); Prostate Cancer (2)
Phase III:
Therapeutic Radiopharmaceuticals: Gastroenteropancreatic Neuroendocrine Tumor (1); Metastatic Hormone Sensitive Prostate Cancer (1); Oligometastatic Prostate Cancer (1). Diagnostic Radiopharmaceuticals: Neuroendocrine Neoplasm (1)
Phase II:
Therapeutic Radiopharmaceuticals: Solid Tumor (1)
Diagnostic Radiopharmaceuticals: Prostate Cancer (1); Solid Tumor (1) Mcrpc (1), Glioblastoma, ES-SCLC (1), Breast Cancer, MST (1), Prostate Cancer (1),
Theranostic Radiopharmaceuticals: Breast Cancer (1)
Phase I:
Therapeutic Radiopharmaceuticals: Solid Tumor (1)
Diagnostic Radiopharmaceuticals: Prostate Cancer (1); Solid Tumor (1) Metastatic Castration-Resistant Prostate Cancer (1), Glioblastoma, ES-SCLC (1), Breast Cancer, MST (1), Prostate Cancer (1)
Theranostic Radiopharmaceuticals: Breast Cancer (1)

Recent Development

In November 2025, Novartis announced the opening of a new radioligand therapy manufacturing facility in California, as part of its USD 23 billion US expansion plan.1

To know more about the recent initiatives of Novartis and other radiopharmaceutical companies, access full report.

2. Telix Pharmaceuticals

Company Overview

Telix Pharmaceuticals boasts a strong pipeline of commercial and developmental assets, leveraging advanced precision medicine and imaging technologies to enhance patient outcomes. The company claims to have one of the largest radiopharmaceutical production facilities in Europe with an area of 2,800 m2, supporting its global manufacturing capabilities. The radiopharmaceuticals portfolio of Telix Pharmaceuticals is centered on Illuccix® for prostate cancer imaging, along with a diverse pipeline targeting kidney, liver, and soft tissue sarcoma. Their innovative agents, such as TLX400 for FAP-expressing tumors, emphasize precision diagnostics and targeted therapies to improve patient outcomes.

Radiopharmaceutical Pipeline

The section provides information on the comprehensive radiopharmaceutical pipeline of Telix, outlining the number of drugs for each therapeutic indication across various stages.

Commercialized Drugs:
Diagnostic Radiopharmaceuticals: Osteomyelitis (1); Prostate Cancer (1)
Phase III:
Diagnostic Radiopharmaceuticals: Prostate Cancer (1); Renal Cell Carcinoma (1)
Therapeutic Radiopharmaceuticals: Metastatic Castration-resistant Prostate Cancer (1)
Phase II:
Therapeutic Radiopharmaceuticals: Renal Cell Carcinoma (1), Glioma (1), Haematological Disease (1)
Diagnostic Radiopharmaceuticals: Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioma, Bile Duct Cancer, Liver Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Soft Tissue Sarcoma (1)
Phase I:
Diagnostic Radiopharmaceuticals: Bladder Cancer (1), Soft Tissue Sarcoma (1)
Therapeutic Radiopharmaceuticals: Bone Cancer (1), Prostate Cancer (1); Bladder Cancer (1) Glioma (1), Soft Tissue Carcinoma (1)

Recent Development:

In January 2025, Telix Pharmaceuticals completed its acquisition of RLS Radiopharmacies, to enhance its production and distribution of precision cancer imaging and therapy agents worldwide.2

To know more about the recent initiatives of Telix Pharmaceuticals and other radiopharmaceutical companies, access full report.

3. Bayer

Company Overview

Bayer is a global life science company specializing in pharmaceuticals, agriculture, and consumer health, driving innovation for a healthier, more sustainable world. Bayer has a growing radiopharmaceutical portfolio focused on innovative therapeutic agents for cancer care, including therapies targeting prostate and ovarian cancer. The company is striving to actively expand its pipeline through strategic collaborations and acquisitions.

Radiopharmaceutical Pipeline

The section provides information on the comprehensive radiopharmaceutical pipeline of Bayer, outlining the number of drugs for each therapeutic indication across various stages.

Commercialized Drugs:
Therapeutic Radiopharmaceuticals: Castration-resistant Prostate Cancer with Bone Metastases (1)
Phase I:
Therapeutic Radiopharmaceuticals: Prostate Cancer (2); Pleural Epithelioid Mesotheliom, Peritoneal Epithelioid Mesothelioma, Ovarian Cancer, Pancreatic Cancer (1)

Recent Development:

In April 2025, Bayer has recently launched a Phase I study using an actinium-225 radiopharmaceutical that targets GPC3 in patients with advanced hepatocellular carcinoma.3

To know more about the recent initiatives of Bayer and other radiopharmaceutical companies, access full report.

4. Lantheus

Company Overview

Lantheus is committed to advancing patient care through cutting-edge diagnostic imaging and targeted therapies. Their robust radiopharmaceuticals portfolio spans oncology, cardiology, and neurology, featuring key products like PYLARIFY® for prostate cancer and Neurolite for stroke detection. Alongside these, emerging therapies such as PNT2003 for gastroenteropancreatic neuroendocrine tumors highlight their innovative approach. Strategic partnerships and acquisitions further strengthen their pipeline, focusing on meeting evolving oncological treatment needs worldwide.

Radiopharmaceutical Pipeline

The section provides information on the comprehensive radiopharmaceutical pipeline of Lantheus, outlining the number of drugs for each therapeutic indication across various stages.

Commercialized Drugs:
Diagnostic Radiopharmaceuticals: Prostate Cancer (1), Hodgkin's Lymphoma,BC, IL (1), Stroke (1), Coronary Artery Disease (1), Imaging of Thyroid, Salivary Gland, Urinary Bladder and NDS (1), Imaging of Pulmonary Function, Cerebral Blood Flow (1)
Phase III:
Diagnostic Radiopharmaceuticals: Alzheimer's Disease (2)
Therapeutic Radiopharmaceuticals: Metastatic Castration-resistant Prostate Cancer (1)
Phase II:
Diagnostic Radiopharmaceuticals: Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Sarcoma (1), Prostate Cancer (1)
Therapeutic Radiopharmaceuticals: Metastatic Castration-resistant Prostate Cancer (1)

Recent Development:

In September 2025, Lantheus has granted GE HealthCare the rights to its blockbuster prostate cancer PET tracer for the Japanese market.4

To know more about the recent initiatives of Lantheus and other radiopharmaceutical companies, access full report.

5. ITM Isotope Technologies

Company Overview

ITM Isotope Technologies is a radiopharmaceutical biotech company specializing in the development, production, and global supply of precision diagnostics and therapeutics for hard-to-treat cancers. Notably, the company claims to possess the world’s largest production site of lutetium-177, an innovative medical isotope used in targeted cancer therapies.

Radiopharmaceutical Pipeline

The section provides information on the comprehensive radiopharmaceutical pipeline of ITM Isotope Technologies, outlining the number of drugs for each therapeutic indication across various stages.

Commercialized Drugs:
Diagnostic Radiopharmaceuticals: Neuroendocrine Tumor (1)
Phase III:
Diagnostic Radiopharmaceuticals: Prostate Cancer (1)
Therapeutic Radiopharmaceuticals: Neuroendocrine Tumor (1), Lung Cancer, Thymus Neoplasms (1)
Phase I:
Diagnostic Radiopharmaceuticals: SSTR Tumor (1), Renal Cell Carcinoma (1), Oncology, Fibrosis, Inflammation (1)
Therapeutic Radiopharmaceuticals: Neuroendocrine Tumor, Blood Cancer, Solid Tumor, CNS Tumor (1), SSTR Tumor (1), Prostate Cancer (2), Glioblastoma (1), Clear Cell Renal Cell Carcinoma (1), Unspecified Cancer (1)

Recent Development:

In November 2025, ITM has received USFDA Fast Track Designation for ITM-94, a diagnostic agent for detecting clear cell renal cell carcinoma (ccRCC).5

To know more about the recent initiatives of ITM Isotope Technologies and other radiopharmaceutical companies, access full report.

What About Other Radiopharmaceutical Companies Around the World?

The above article features few prominent companies developing radiopharmaceuticals selected from a pool of over 100 drug developers that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources

1. https://www.novartis.com/news/media-releases/novartis-opens-new-radioligand-therapy-manufacturing-facility-california-part-23b-us-expansion-plan
2. https://www.globenewswire.com/news-release/2025/01/27/3016008/0/en/Telix-Completes-Acquisition-of-RLS-USA-Inc.html
3. https://www.bayer.com/media/en-us/bayer-initiates-phase-i-study-targeting-gpc3-with-actinium-225-radiopharmaceutical-in-patients-with-advanced-hepatocellular-carcinoma/
4. https://www.fiercebiotech.com/medtech/lantheus-hands-ge-healthcare-rights-its-blockbuster-prostate-cancer-pet-tracer-japan
5. https://www.globenewswire.com/news-release/2025/11/17/3188899/0/en/ITM-Receives-U-S-FDA-Fast-Track-Designation-for-ITM-94-as-a-Diagnostic-Agent-for-Clear-Cell-Renal-Cell-Carcinoma.html